Lundbeck is ceasing its sales and marketing operations in India, reports the domestic business media Economic Times.
The division, based in Bengaluru, employs around 100 people, and Lundbeck informs that the shutdown is a part of its strategy, it writes in an email to the Indian media.
"Lundbeck has decided to exit its operations in India, in line with our strategy. We will continue to serve the market in India per local regulatory requirements, however the medicines that we offer in India also have suitable alternatives," writes Lundbeck.
Lundbeck launched its antidepressant drug Brintellix in India back in 2018, however, the Danish pharmaceutical company decided in 2015 to withdraw its Central Asian production and return to Denmark.
Lundbeck wins patent case against six generic medicine producers
Lundbeck hopes long-term Covid-19 effects will boost Trintellix
More from MedWatch
"Real world" patient data documents the long-term effects of ALK vaccines
In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers.
Y-mabs CEO has big ambitions: Wants to create the Tesla of biotech
CEO at Y-mabs Claus Møller sees the potential to create "the Tesla within biotechnology" in the Danish-American cancer company, as reported by Danish media Børsen.
Contact with consumers will secure continued growth in China, says Sonova
Hearing aid manufacturer Sonova says direct contact with consumers on the growing Chinese market will be the way forward to increase growth.
AGC's Japanese and Danish factories to produce German biotech firm's drug candidate
German 4teen4 has chosen AGC Biologics as contract developer for the clinical testing of its drug candidate, procizumab.
EMA begins rolling review of another Covid-19 vaccine
The European Medicines Agency will assess the potential vaccine being developed by Valneva as data trickles in.
CMC Stability Specialist 
Regulatory Science Specialist 
QA Specialist, GMP QA 
GxP QA Compliance Manager for Quality Assurance 
Regulatory documentation Specialist 
Clinical Bioinformatician 
Senior Manager/Associate Director Regulatory Affairs 
Join us! And start to impact healthcare through innovation 
Procurement Manager 
Area Sales Manager, Life Sciences, BU Øresund Region 
Nordic Field Sales Manager 
Director Regulatory Affairs 
Manager, R&D & Global Quality Applications 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Senior Clinical Trial Manager